Hexarelin

Hexarelin (Examorelin) is a synthetic hexapeptide growth hormone secretagogue that acts primarily through the ghrelin receptor (GHS-R1a). Among the GHRP family of peptides, Hexarelin is widely recognized as producing the most potent acute growth hormone release. Single doses can elicit GH peaks significantly higher than those achieved with GHRP-2 or GHRP-6, making it an important research tool for studying maximal GH secretory capacity.

Despite its potency, Hexarelin has a notable limitation: it tends to cause desensitization (tachyphylaxis) with repeated use. Studies have shown that the GH response to Hexarelin diminishes significantly over weeks of continuous administration, even though it does not completely disappear. This desensitization effect is more pronounced with Hexarelin than with other GHS peptides, which has limited its practical utility for sustained GH elevation in clinical and off-label settings.

One of the most interesting aspects of Hexarelin research involves its cardioprotective properties. Studies have demonstrated that Hexarelin binds to a specific cardiac receptor (CD36), distinct from the GHS-R1a receptor, and can exert protective effects on cardiac tissue independent of GH release. Research in animal models of heart failure and ischemia has shown Hexarelin can improve cardiac function, reduce ventricular remodeling, and protect against ischemia-reperfusion injury. These cardiac effects represent a unique therapeutic dimension not shared by all GH secretagogues.

Clinical research on Hexarelin has been conducted in various populations, including healthy adults, elderly subjects, and patients with GH deficiency. Studies have confirmed its potent GH-releasing activity and characterized its effects on cortisol, prolactin, and ACTH. While it was investigated for potential commercialization by Mediolanum Farmaceutici, it was never approved for clinical use. Its primary role remains as a research compound and an option for short-term GH optimization protocols.